Compare PZZA & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZZA | ABCL |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1995 | 2020 |
| Metric | PZZA | ABCL |
|---|---|---|
| Price | $34.80 | $4.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $45.00 | $8.40 |
| AVG Volume (30 Days) | 665.1K | ★ 5.3M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $2,068,421,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.85 |
| P/E Ratio | $39.59 | ★ N/A |
| Revenue Growth | 14.07 | ★ 160.56 |
| 52 Week Low | $30.16 | $1.94 |
| 52 Week High | $55.74 | $6.52 |
| Indicator | PZZA | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 70.60 |
| Support Level | $30.47 | $3.93 |
| Resistance Level | $34.89 | $4.84 |
| Average True Range (ATR) | 1.41 | 0.26 |
| MACD | -0.29 | 0.05 |
| Stochastic Oscillator | 9.04 | 89.30 |
Papa John's International Inc operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants. It has four defined reportable segments: Domestic Company-owned restaurants, North America franchising, North America commissaries, and International. The company derives maximum revenue from North America commissaries segment. The North America commissaries segment consists of the operations of its regional dough production and product distribution centers in the United States and Canada and derives its revenues principally from the sale and distribution of food and paper products to Domestic Company-owned and franchised restaurants in the United States and Canada.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.